These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 3407596)
1. Dopexamine hydrochloride in chronic congestive heart failure with improved cardiac performance without increased metabolic cost. De Marco T; Kwasman M; Lau D; Chatterjee K Am J Cardiol; 1988 Aug; 62(5):57C-62C. PubMed ID: 3407596 [TBL] [Abstract][Full Text] [Related]
2. [Dopexamine: a new dopaminergic agonist]. Perrin G; Papazian L; Martin C Ann Fr Anesth Reanim; 1993; 12(3):308-20. PubMed ID: 7902685 [TBL] [Abstract][Full Text] [Related]
3. Inotropic, vascular and neuroendocrine effects of dopexamine hydrochloride and comparison with dobutamine. Jaski BE; Peters C Am J Cardiol; 1988 Aug; 62(5):63C-67C. PubMed ID: 3407597 [TBL] [Abstract][Full Text] [Related]
4. Role of the beta 2 adrenoceptor in mediating positive inotropic activity in the failing heart and its relation to the hemodynamic actions of dopexamine hydrochloride. Lang RM; Borow KM; Neumann A; Carroll JD; Weinert L; Murphy MB; Ghali J; Rajfer SI Am J Cardiol; 1988 Aug; 62(5):46C-52C. PubMed ID: 2841838 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study. Gollub SB; Elkayam U; Young JB; Miller LW; Haffey KA J Am Coll Cardiol; 1991 Aug; 18(2):383-90. PubMed ID: 1677368 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the haemodynamic effects of dopexamine and dobutamine in patients with severe congestive heart failure. Tan LB; Littler WA; Murray RG Int J Cardiol; 1991 Feb; 30(2):203-8. PubMed ID: 2010243 [TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of dopexamine hydrochloride infusions of 48 to 72 hours' duration for severe congestive heart failure. Gollub SB; Emmot WW; Johnson DE; Sights KA; Wilson DB; Vacek JL; Hassanein K Am J Cardiol; 1988 Aug; 62(5):83C-88C. PubMed ID: 3407599 [TBL] [Abstract][Full Text] [Related]
8. Central and renal hemodynamic effects of a new agonist at peripheral dopamine- and beta-2 adrenoreceptors (dopexamine) in patients with heart failure. Jamison M; Widerhorn J; Weber L; Campese V; Vasquez J; Hovanessian L; Rahimtoola SH; Elkayam U Am Heart J; 1989 Mar; 117(3):607-14. PubMed ID: 2537556 [TBL] [Abstract][Full Text] [Related]
9. Effects of dopexamine on hemodynamics and oxygen consumption after beta blockade in lambs. Taylor BJ; Rogers BW; Sziszak TL; Sziszak TJ Crit Care Med; 1993 May; 21(5):733-9. PubMed ID: 8386999 [TBL] [Abstract][Full Text] [Related]
10. Short-term haemodynamic effects of dopexamine in patients with chronic congestive heart failure. Svensson G; Sjögren A; Erhardt L Eur Heart J; 1986 Aug; 7(8):697-703. PubMed ID: 2876894 [TBL] [Abstract][Full Text] [Related]
11. Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. Rude RE; Turi Z; Brown EJ; Lorell BH; Colucci WS; Mudge GH; Taylor CR; Grossman W Circulation; 1981 Jul; 64(1):139-45. PubMed ID: 7237712 [TBL] [Abstract][Full Text] [Related]
12. Clinical development of dopexamine hydrochloride (Dopacard) and an overview of its hemodynamic effects. Foulds RA Am J Cardiol; 1988 Aug; 62(5):41C-45C. PubMed ID: 3044060 [TBL] [Abstract][Full Text] [Related]
13. Comparison of acute haemodynamic effects of dopexamine hydrochloride, dobutamine and sodium nitroprusside in chronic heart failure. Baumann G; Gutting M; Pfafferott C; Ningel K; Klein G Eur Heart J; 1988 May; 9(5):503-12. PubMed ID: 3402466 [TBL] [Abstract][Full Text] [Related]
14. Systemic and coronary hemodynamic and neurohumoral effects of levodopa in chronic congestive heart failure. De Marco T; Daly PA; Chatterjee K Am J Cardiol; 1988 Dec; 62(17):1228-33. PubMed ID: 2904216 [TBL] [Abstract][Full Text] [Related]
15. Use of dopexamine hydrochloride in intensive care patients with low-output left ventricular heart failure. Colardyn FA; Vandenbogaerde JF Am J Cardiol; 1988 Aug; 62(5):68C-72C. PubMed ID: 3407598 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular pharmacology of dopexamine in low output congestive heart failure. Leier CV; Binkley PF; Carpenter J; Randolph PH; Unverferth DV Am J Cardiol; 1988 Jul; 62(1):94-9. PubMed ID: 2898209 [TBL] [Abstract][Full Text] [Related]
17. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure. Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928 [TBL] [Abstract][Full Text] [Related]
18. [Acute reduction of increased atrial natriuretic peptide level and cyclic guanosine monophosphate in patients with chronic heart failure caused by beta-adrenergic stimulation with dopexamine hydrochloride. Correlation with hemodynamic parameters]. Stangl K; Baumann G; Weil J; Gerzer R; Kerscher M; Blömer H Z Kardiol; 1990 Jun; 79(6):417-23. PubMed ID: 1974099 [TBL] [Abstract][Full Text] [Related]
19. Effects of atrial natriuretic factor on coronary hemodynamics and myocardial energetics in patients with heart failure. Herrmann HC; Palacios IF; Dec GW; Scheer JM; Fifer MA Am Heart J; 1988 Jun; 115(6):1232-8. PubMed ID: 2967626 [TBL] [Abstract][Full Text] [Related]
20. Dopexamine hydrochloride after coronary artery bypass grafting. van der Starre PJ; Rosseel PM Am J Cardiol; 1988 Aug; 62(5):78C-82C. PubMed ID: 3261535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]